MIC-1 and Leptin Combination for Obesity Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for controlling body weight and treating Type 2 diabetes are inadequate, as they fail to effectively address the complex interplay of factors influencing appetite and energy homeostasis, particularly in obese individuals with altered leptin levels.
Innovation Solution
A composition comprising MIC-1 and/or active MIC-1 fragments combined with leptin and/or active leptin fragments, administered alone or in combination, to modulate body weight and appetite, specifically targeting subjects with diet-induced obesity, Type 2 diabetes, and related complications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods for controlling body weight are used, then treatment is provided, but they fail to effectively address the complex interplay of factors influencing appetite and energy homeostasis
Solution Approach 1:
The patent combines MIC-1 and leptin into a single composition to simultaneously address multiple factors in body weight control. MIC-1 acts on the hypothalamus to reduce appetite, while leptin regulates energy homeostasis, creating a synergistic effect that overcomes the limitations of single-agent therapies.
Solution Approach 2:
The invention uses a composite therapeutic approach by formulating a composition containing both MIC-1 and leptin. This composite composition allows the two agents to work together to address the complex multifactorial nature of obesity, including appetite regulation and energy expenditure, providing a more comprehensive treatment than individual agents alone.
2Productivity
If MIC-1 is administered alone, then appetite is reduced, but the effect is insufficient in subjects with altered leptin levels
Solution Approach 1:
Leptin serves as an intermediary that bridges the gap in MIC-1's effectiveness. By including leptin in the composition, the patent ensures that subjects with altered leptin levels (such as leptin resistance or deficiency) receive the necessary signaling to complement MIC-1's appetite-suppressing effects, thereby ensuring consistent therapeutic outcomes across different patient populations.
Solution Approach 2:
The patent addresses variability in leptin levels by incorporating leptin directly into the composition. This allows for controlled delivery of appropriate leptin amounts to subjects with different baseline leptin levels, ensuring that the therapeutic effect of MIC-1 is maintained regardless of the subject's endogenous leptin status.
3Productivity
If combination therapy is used, then weight loss is enhanced, but treatment complexity increases
Solution Approach 1:
The patent merges MIC-1 and leptin into a single integrated composition, which simplifies the treatment regimen despite the complexity of the combination therapy. Instead of requiring separate administration of two agents, the unified composition allows for simultaneous delivery of both agents in the correct proportions, reducing the complexity of treatment administration while maintaining the enhanced weight loss efficacy of combination therapy.
Data Source
Figure 1A~2
Figure 3A~4C
Figure 5A~5C
AI summary
Methods for controlling body weight and/or appetite in a subject are disclosed. In some embodiments, the methods involve administering to an overweight or obese subject an effective amount of a first agent comprising MIC-1, a MIC- 1 agonist and/or a MIC-1-inducing agent, and a second agent comprising leptin and/or a leptin agonist, for the purpose of achieving weight loss. In other embodiments, the methods involve administering to an anorexic or cachectic subject an effective amount of a MIC-1-inhibiting agent and a leptin-inhibiting agent, for the purpose of increasing body weight and/or appetite in a subject.